Skip to main content

Table 4 Results (Patients with continuous PSA follow up in all 3 intervals)

From: Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

   

SBRT

CF-EBRT

p-value

  

Through year

   

# Evaluable patients with PSA

26

37

 

Follow-up for All 3 intervals

    

PSA measurements

    
 

Mean (range)

1

3.8 (2 – 5)

4.2 (3 – 11)

 
  

2

5.8 (4 – 8)

6.6 (4 – 15)

 
  

3

7.6 (5 – 11)

9.0 (6 – 21)

p = 0.03#

Nadir PSA (ng/mL)

    
 

Median (range)

1

0.81 (0.1 – 2.5)

1.00 (0 – 8.5)

 
  

2

0.45 (0.1 – 1.4)

0.86 (0 – 2.5)

p = 0.02*

  

3

0.25 (0.1 – 1.4)

0.70 (0 – 2.2)

p = 0.002*

Time to Nadir PSA (mos.)

    
 

Median (range)

1

12.0 (2.7 – 15.0)

11.5 (1.2 – 15.0)

 
  

2

22.1 (2.7 – 26.9)

17.9 (1.2 – 26.9)

 
  

3

31.5 (2.7 – 41.6)

27.4 (1.2 – 41.0)

p = 0.02^

Rate of PSA change: ng/mL/month

   
 

Median slope (range)

1

-0.08 (-0.88, 0.04)

-0.09 (-0.60, 0.06)

 
  

2

-0.06 (-0.38, 0.004)

-0.04 (-0.65, 0.05)

 
  

3

-0.05 (-0.19, 0.001)

-0.03 (-0.38, 0.02)

 
  1. SBRT: Stereotactic Body Radiotherapy.
  2. CF-EBRT: Conventionally fractionated external beam radiotherapy.
  3. p: Statistical significance.
  4. # The t test was performed to compare the mean number of PSA measurements between the two groups for each interval with means and ranges presented to summarize the results.
  5. ^ The log rank test was used due to compare the time to nadir PSA distributions between the two groups for each interval with medians and ranges presented to summarize the results.
  6. * The Mann–Whitney test was performed to compare the PSA nadir and slope distributions between the two groups with medians and ranges presented to summarize the results.